ERCC1 Expression Does Not Predict Survival and Treatment Response in Advanced Stage Non-Small Cell Lung Cancer Cases Treated with Platinum Based Chemotherapy
Authors:
- Ozer OzdemirOOOzer Ozdemir
- Pelin OzdemirPOPelin Ozdemir
- Ali VeralAVAli Veral
- Hatice UluerHUHatice Uluer
- Mustafa Hikmet OzhanMOMustafa Hikmet Ozhan
Open Access
- 30 August 2013
- journal article
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 14 (8) , 4679-4683
Abstract
ERCC1 Expression Does Not Predict Survival and Treatment Response in Advanced Stage Non-Small Cell Lung Cancer Cases Treated with Platinum Based Chemotherapy Non-small cell lung cancer;lung cancer chemotherapy;ERCC1;molecular markers; Background: ERCC1 is considered as a promising molecular marker that may predict platinum based chemotherapy response in non small cell lung cancer patients. We therefore investigated whether its expression is indeed associated with clinical outcomes in advanced stage NSCLC patients. Materials and Methods: Pretreatment tumor biopsy samples of 83 stage 3B and 4 non-small cell lung cancer patients treated with platinum based chemotherapy were retrospectively analyzed for immunohistochemical ERCC1 expression. None of the patients received curative surgery or radiotherapy. Results: By calculating H- scores regarding the extent and intensity of immunohistochemical staining of tumor biopsy samples, ERCC1 expression was found to be positive in 50 patients (60.2%). ERCC1 positive and negative groups had no statistically significant differences regarding treatment response, progression free survival and overall survival (respectively p=0.161; p=0.412; p=0.823). Conclusions: In our study we found no association between ERCC1 expression and survival or treatment response. The study has some limitations, such as small sample size and retrospective analysis method. There is need of more knowledge for use of ERCC1 guided chemotherapy regimens in advanced stage NSCLC.Keywords
This publication has 23 references indexed in Scilit:
- Randomized International Phase III Trial of ERCC1 and RRM1 Expression–Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2013
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2013
- ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancerExperimental and Therapeutic Medicine, 2011
- The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysisLung Cancer, 2010
- Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic SitesJournal of Thoracic Oncology, 2009
- The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer☆European Journal of Cardio-Thoracic Surgery, 2008
- Molecular Analysis-Based Treatment Strategies for Non–Small Cell Lung CancerCancer Control, 2008
- The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabineAnnals of Oncology, 2006
- Prognostic Significance of Molecular Genetic Aberrations on Chromosome Segment 11p15.5 in Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2002